Healthcare · Pharmaceuticals: Major

VRVertex Pharmaceuticals Incorporated

NASDAQVRTX ISINUS92532F1003 SEC CIK0000875320 Listed on NASDAQ · USD

$548.07 +1.04 (+0.19%) Pre-market $547.49 (+0.08%) ≈ ₹51,437 a share

Open chart

Price, last 12 months+33.59% in a year

Key numbers

Market value: $138.96B
P/E (TTM): 35.3
Forward P/E: 29.8
EPS (TTM): $15.54
Dividend yield: —
Beta: 0.28
Day range: $543.13 – $552.27
52-week range: $412.27 – $568.67
Volume: 163,931
10-day avg volume: $1.93M
Revenue (TTM): $12.95B
EBITDA (TTM): $4.66B
Gross margin: 85.5%
Net margin: 30.7%
Return on equity: 20.8%
Debt / equity: 21.5%
Price / sales: 10.73
Shares out: 253.54M

52W low52W high

Quarterly results

Results for each quarter

Last 12 quarters from 10-Q and 10-K filings with the US SEC. Q4 = full year minus the first three quarters. Hover a bar to see the number.

Revenue and net income

$2.52B$988.50M$968.80M

Dec 23

$2.69B$1.14B$1.10B

Mar 24

$2.65B$-3.51B$-3.59B

Jun 24

$2.77B$1.12B$1.05B

Sep 24

$2.91B$1.03B$913.00M

Dec 24

$2.77B$630.10M$646.30M

Mar 25

$2.96B$1.15B$1.03B

Jun 25

$3.08B$1.19B$1.08B

Sep 25

$3.19B$1.21B$1.19B

Dec 25

$2.99B$1.14B$1.03B

Mar 26

$3.33B$1.25B$1.10B

Jun 26

$3.44B$712.90M$653.60M

Sep 26

Revenue · QoQ (vs last quarter)

—+6.9%-1.7%+4.8%+5.1%-4.9%+7.0%+3.8%+3.7%-6.4%+12%+3.2%

Revenue · YoY (vs a year ago)

————+16%+3.0%+12%+11%+9.5%+7.8%+12%+12%

Net income · QoQ (vs last quarter)

—+14%-427%+129%-13%-29%+60%+4.8%+10.0%-13%+6.6%-41%

Net income · YoY (vs a year ago)

————-5.8%-41%+129%+3.6%+30%+60%+6.5%-40%

RevenueOperating incomeNet incomeLine = trend

US$	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	$2.52B	$2.69B	$2.65B	$2.77B	$2.91B	$2.77B	$2.96B	$3.08B	$3.19B	$2.99B	$3.33B	$3.44B
Cost of revenue	$368.00M	$342.60M	$371.90M	$392.60M	$423.40M	$363.00M	$407.50M	$414.80M	$466.00M	$392.80M	$489.20M	$526.10M
Gross profit	$2.15B	$2.35B	$2.27B	$2.38B	$2.49B	$2.41B	$2.56B	$2.66B	$2.72B	$2.59B	$2.84B	$2.91B
Gross margin	85.4%	87.3%	85.9%	85.8%	85.5%	86.9%	86.3%	86.5%	85.4%	86.8%	85.3%	84.7%
Selling, general & admin	$369.10M	$342.70M	$372.20M	$371.80M	$377.60M	$396.40M	$424.60M	$445.10M	$487.00M	$493.70M	$582.20M	$844.10M
Operating income	$988.50M	$1.14B	$-3.51B	$1.12B	$1.03B	$630.10M	$1.15B	$1.19B	$1.21B	$1.14B	$1.25B	$712.90M
Operating margin	39.3%	42.4%	-132.9%	40.3%	35.2%	22.7%	38.8%	38.6%	37.8%	38.1%	37.4%	20.7%
Interest expense	—	$10.40M	$9.90M	$7.50M	$2.80M	$3.00M	$3.70M	$3.30M	$3.30M	—	—	$36.00M
Pre-tax income	$1.15B	$1.28B	$-3.39B	$1.22B	$1.14B	$730.40M	$1.28B	$1.30B	$1.33B	$1.25B	$1.39B	$783.40M
Income tax	$178.80M	$179.50M	$202.40M	$178.70M	$223.50M	$84.10M	$250.10M	$215.90M	$139.90M	$221.50M	$292.00M	$129.80M
Net income	$968.80M	$1.10B	$-3.59B	$1.05B	$913.00M	$646.30M	$1.03B	$1.08B	$1.19B	$1.03B	$1.10B	$653.60M
Net margin	38.5%	40.9%	-135.8%	37.7%	31.4%	23.3%	34.8%	35.2%	37.3%	34.5%	33.0%	19.0%
EPS (diluted)	—	$4.21	$-13.92	$4.01	—	$2.49	$3.99	$4.20	—	$4.02	$4.31	$2.56

Income statement

Results for each year

8 fiscal years from the company's 10-K filings with the US SEC.

Revenue, gross profit and net income

$3.05B$2.64B$2.10B

FY18

$4.16B$3.62B$1.18B

FY19

$6.21B$5.47B$2.71B

FY20

$7.57B$6.67B$2.34B

FY21

$8.93B$7.85B$3.32B

FY22

$9.87B$8.61B$3.62B

FY23

$11.02B$9.49B$-535.60M

FY24

$12.00B$10.35B$3.95B

FY25

Revenue · YoY (vs a year ago)

—+37%+49%+22%+18%+11%+12%+8.9%

Net income · YoY (vs a year ago)

—-44%+130%-14%+42%+9.0%-115%+838%

RevenueGross profitNet incomeLine = trend

$8.09

FY18

$4.51

FY19

$10.29

FY20

$9.01

FY21

$12.82

FY22

$13.89

FY23

$-2.08

FY24

$15.32

FY25

EPS (diluted) · YoY (vs a year ago)

—-44%+128%-12%+42%+8.3%-115%+837%

EPS (diluted)Line = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Revenue	$3.05B	$4.16B	$6.21B	$7.57B	$8.93B	$9.87B	$11.02B	$12.00B
Revenue growth	—	36.6%	49.1%	22.1%	17.9%	10.5%	11.7%	8.9%
Cost of revenue	$409.54M	$547.80M	$736.30M	$904.20M	$1.08B	$1.26B	$1.53B	$1.65B
Gross profit	$2.64B	$3.62B	$5.47B	$6.67B	$7.85B	$8.61B	$9.49B	$10.35B
Gross margin	86.6%	86.8%	88.1%	88.1%	87.9%	87.2%	86.1%	86.2%
Research & development	$1.42B	$1.75B	$1.83B	$3.05B	—	—	—	—
Selling, general & admin	$557.62M	$658.50M	$770.50M	$840.10M	$944.70M	$1.14B	$1.46B	$1.75B
Operating income	$635.15M	$1.20B	$2.86B	$2.78B	$4.31B	$3.83B	$-232.90M	$4.17B
Operating margin	20.8%	28.8%	46.0%	36.7%	48.2%	38.8%	-2.1%	34.8%
Depreciation & amortisation	$72.42M	$106.90M	$109.50M	$125.60M	$148.30M	$181.30M	$207.20M	$209.80M
Interest expense	$72.47M	$58.50M	$58.15M	—	$54.80M	$44.10M	$30.60M	$13.30M
Pre-tax income	$600.24M	$1.39B	$3.12B	$2.73B	$4.23B	$4.38B	$248.50M	$4.64B
Income tax	$-1.49B	$218.10M	$405.20M	$388.30M	$910.40M	$760.20M	$784.10M	$690.00M
Tax rate	-247.7%	15.6%	13.0%	14.2%	21.5%	17.4%	315.5%	14.9%
Net income	$2.10B	$1.18B	$2.71B	$2.34B	$3.32B	$3.62B	$-535.60M	$3.95B
Net margin	68.8%	28.3%	43.7%	30.9%	37.2%	36.7%	-4.9%	32.9%
EPS (diluted)	$8.09	$4.51	$10.29	$9.01	$12.82	$13.89	$-2.08	$15.32

Balance sheet

Assets and debt

At each fiscal year end.

Equity, debt and cash

$4.44B$3.17B

FY18

$6.09B$3.81B

FY19

$8.69B$6.66B

FY20

$10.10B$7.52B

FY21

$13.91B$10.78B

FY22

$17.58B$11.22B

FY23

$16.41B$6.12B

FY24

$18.67B$0$6.61B

FY25

Shareholders' equity · YoY (vs a year ago)

—+37%+43%+16%+38%+26%-6.7%+14%

Shareholders' equityTotal debtCash + short-term investmentsLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash & equivalents	$2.65B	$3.11B	$5.99B	$6.80B	$10.50B	$10.37B	$4.57B	$5.08B
Short-term investments	$518.11M	$698.97M	$670.70M	$729.90M	$274.50M	$849.20M	$1.55B	$1.52B
Current assets	$3.84B	$4.82B	$8.13B	$9.56B	$13.23B	$14.14B	$9.60B	$11.20B
Total assets	$6.25B	$8.32B	$11.75B	$13.43B	$18.15B	$22.73B	$22.53B	$25.64B
Current liabilities	$1.12B	$1.33B	$1.88B	$2.14B	$2.74B	$3.55B	$3.56B	$3.86B
Long-term debt	—	—	—	—	—	—	—	$0
Short-term debt	—	—	—	—	—	—	—	$0
Total debt	—	—	—	—	—	—	—	$0
Total liabilities	$1.81B	$2.23B	$3.07B	$3.33B	$4.24B	$5.15B	$6.12B	$6.98B
Shareholders' equity	$4.44B	$6.09B	$8.69B	$10.10B	$13.91B	$17.58B	$16.41B	$18.67B
Current ratio	3.43	3.61	4.33	4.46	4.83	3.99	2.69	2.90
Debt / equity	—	—	—	—	—	—	—	0.00
Return on equity	47.3%	19.3%	31.2%	23.2%	23.9%	20.6%	-3.3%	21.2%

Cash flow

Cash coming in and going out

Free cash flow = cash from operations minus capital spending. Shareholder returns = dividends + buybacks.

Free cash flow and shareholder returns

$1.27B$1.17B$350.04M

FY18

$1.57B$1.49B$186.00M

FY19

$3.25B$2.99B$539.10M

FY20

$2.64B$2.41B$1.43B

FY21

$4.13B$3.93B$0

FY22

$3.54B$3.34B$427.60M

FY23

$-492.60M$-790.30M$1.18B

FY24

$3.63B$3.19B$2.02B

FY25

Operating cash flow · YoY (vs a year ago)

—+24%+107%-19%+56%-14%-114%+837%

Free cash flow · YoY (vs a year ago)

—+27%+100%-20%+63%-15%-124%+504%

Operating cash flowFree cash flowDividends + buybacksLine = trend

US$	FY18	FY19	FY20	FY21	FY22	FY23	FY24	FY25
Cash from operations	$1.27B	$1.57B	$3.25B	$2.64B	$4.13B	$3.54B	$-492.60M	$3.63B
Capital spending	$-95.45M	$-75.40M	$-259.80M	$-235.00M	$-204.70M	$-200.40M	$-297.70M	$-437.60M
Free cash flow	$1.17B	$1.49B	$2.99B	$2.41B	$3.93B	$3.34B	$-790.30M	$3.19B
FCF margin	38.5%	35.9%	48.2%	31.8%	44.0%	33.8%	-7.2%	26.6%
Stock-based pay	$325.05M	$360.50M	$429.50M	$441.40M	$491.30M	$581.20M	$698.50M	$685.90M
Cash from investing	$-202.16M	$-1.24B	$99.40M	$-340.90M	$-321.10M	$-3.14B	$-3.77B	$-945.40M
Cash from financing	$-71.22M	$126.80M	$-505.30M	$-1.48B	$-67.70M	$-562.20M	$-1.49B	$-2.26B
Share buybacks	$-350.04M	$-186.00M	$-539.10M	$-1.43B	$0	$-427.60M	$-1.18B	$-2.02B

About

About Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals Incorporated is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry. It maintains headquarters in Boston, Massachusetts, and three research facilities, in San Diego, California, and Milton Park, Oxfordshire, England.

From Wikipedia (CC BY-SA 4.0).

Company details

Company name: Vertex Pharmaceuticals Incorporated
Ticker: VRTX
Exchange: NASDAQ
ISIN: US92532F1003
SEC CIK: 0000875320
Sector: Healthcare
Industry: Pharmaceuticals: Major
SEC industry (SIC): Pharmaceutical Preparations (2834)
Incorporated in: Massachusetts
Financial year ends: 31 December
Filer type: Large accelerated filer
Latest annual report (10-K): 13 Feb 2026
CEO: Reshma Kewalramani
Chair: Jeffrey M. Leiden
Headquarters: Boston
Address: 50 Northern Avenue, Boston, Ma 02210
Founded: 1989
Employees: 6,400
Trades in: US dollars (USD)
Website: vrtx.com

News

Peers

Others in Healthcare

Quotes from CNBC (may be delayed), financials from SEC EDGAR, profile from global-stock-logos (MIT). Information only, not investment advice.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

VRVertex Pharmaceuticals Incorporated

Key numbers

Quarterly results

Revenue and net income

Income statement

Revenue, gross profit and net income

Balance sheet

Equity, debt and cash

Cash flow

Free cash flow and shareholder returns

About

Company details

News

Peers